Compare Biogen Inc (BIIB) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Oklo Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Oklo Inc trades at $45.29 (market cap $8.74B). The key difference: Biogen Inc is far larger — about 3.4× Oklo Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | OKLO | |
|---|---|---|
Market Cap | $30.13B | $8.74B |
Sector | Health | Technology |
52-Week High | $216.63 | $174.14 |
52-Week Low | $128.93 | $36.84 |
Enterprise Value | $37.20B | $6.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
OKLO trades at $45.13, up 1.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $77.07. The company reported its first revenue of $1.2 million in Q2 2026 but posted a wider net loss of $0.28 per share, missing estimates. Key milestones include the Groves reactor achieving criticality, though cash burn remains high with operating cash flow negative $117 million in 2026.
The outlook balances significant growth potential in nuclear energy against substantial execution risks. Analyst sentiment is strongly bullish (77% buy ratings), but investors face risks from persistent losses, high spending, and project delays. The stock's trajectory hinges on successful commercialization of its Aurora reactors by the targeted 2028 startup.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
